Wendy Perrow

Wendy Perrow is the current Chief Executive Officer and Board Member of AsclepiX Therapeutics, Inc. Wendy has been with the company since July 2016.

AsclepiX Therapeutics is focused on transforming the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies which may empower patients and families around the world with the freedom to live their best lives.

Under Wendy's leadership, the company has raised $21 million via non-dilutive and private investor funding, and they have negotiated an exclusive license from Johns Hopkins University for the development of novel therapeutics in ophthalmology and oncology. Wendy has also created and led a successful development of AXT107 ophthalmology programs in collaboration with FDA for novel toxicology program and animal models.

In addition, Wendy has spearheaded innovative formulation of new products in-house and global GMP manufacturing of AXT107. Wendy has also championed a small high-performing team to progress three novel products from concept to pre-clinical studies.

Wendy Perrow has a M.B.A. in Finance and Marketing from Duke University - The Fuqua School of Business.

Wendy Perrow works with Gary Musso - Manufacturing / CMC, Patrick H. Griffin - Chief Medical Officer, and Kendyle Woodard - Co-founder and Executive Vice President, Corporate Affairs. Wendy Perrow reports to Sandeep Laumas, Executive Chairman and Chief Executive Officer.